Lewes, DE -- (SBWIRE) -- 07/29/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Save the World Air Inc (OTCBB:ZERO), Epazz Inc (OTCMKTS:EPAZ), Generex Biotechnology Corporation (OTCMKTS:GNBT), Baylake Corporation (OTCBB:BYLK)
Save the World Air Inc (OTCBB:ZERO) recorded a fall of -3.94% and was in a range of $1.15-$1.25 before closing at $1.22. The stock completed the day with a total volume of 87,428 shares versus an average volume of 135,437 shares. The share price hit its 52-week low of $0.42 and $1.92 was the best price. Save The World Air, Inc., a development stage enterprise, engages in designing, licensing, and developing products to commercialize energy efficient technologies. It offers energy efficiency technologies that assist in meeting global energy demands, improving the economics of oil extraction and transport, and reducing greenhouse gas emissions.
Is it the Right to Grab ZERO after the Recent Slump? Get Free Trend Analysis Here
Epazz Inc (OTCMKTS:EPAZ) added 5.56%, bringing its market capitalization around $3.05 million. The share price after opening at $0.0018 made a high of $0.0022 and hovered above $0.0017 to end the day at $0.0019. The total number of shares changed hands during the session was 53.73 million shares as compared to average trading volume of 13.46 million shares. Epazz, Inc. (EPAZ), a leading provider of cloud based business software solutions, announced that it has been working on a new product called "Human Power." Project Human Power is a new mobile power device. The product is not directly in line with Epazz's core business. Therefore, management believes it is a great opportunity to be the second Epazz spin-off.
For How Long EPAZ will fight for Profitability? Read This Trend Analysis report
Generex Biotechnology Corporation (OTCMKTS:GNBT) recorded a fall of -2.63% and was in a range of $0.04-$0.04 before closing at $0.0370. The stock completed the day with a total volume of 6.69 million shares versus an average volume of 2.98million shares. The share price hit its 52-week low of $0.02 and $0.09 was the best price. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Why Should Investors Buy GNBT After the Recent Fall? Just Go Here and Find Out
Baylake Corporation (OTCBB:BYLK) declined -0.10%, bringing its market capitalization around $80.09 million. The share price after opening at $10.05 made a high of $10.05 and hovered above $10.02 to end the day at $10.05. The total number of shares changed hands during the session was 23,858 shares as compared to average trading volume of 6,615 shares. Baylake Corp. operates as the holding company for Baylake Bank that provides financial services primarily to small businesses and individuals in Wisconsin. It provides various depository products, including non-interest bearing demand deposits, interest-bearing demand deposits, savings and money market accounts, and certificates of deposit.
Will BYLK Get Buyers Even After The Recent Rally? Find Out Here
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/